Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,57 USD | -1,88% | -3,09% | +11,35% |
15/03 | ATYR PHARMA, INC. : Een koopadvies van RBC Capital Markets | ZM |
14/03 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Omzet 2024 * | 2,62 mln. 2,46 mln. | Omzet 2025 * | 9,26 mln. 8,68 mln. | Marktkapitalisatie | 107 mln. 100 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -62 mln. -58,13 mln. | Nettowinst (verlies) 2025 * | -67 mln. -62,82 mln. | EV/omzet 2024 * | 40,6 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 11,5 x |
K/w-verhouding 2024 * |
-1,58
x | K/w-verhouding 2025 * |
-1,67
x | Werknemers | 58 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 97,38% |
Recentste transcriptie over aTyr Pharma, Inc.
1 dag | -1,88% | ||
1 week | -3,09% | ||
1 maand | -19,49% | ||
3 maanden | -1,57% | ||
6 maanden | +25,60% | ||
Lopend jaar | +11,35% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 30-03-16 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 30-07-18 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 08-09-05 |
Tim Coughlin
CHM | Chairman | 57 | 10-04-17 |
John Clarke
BRD | Director/Board Member | 70 | 01-09-05 |
Datum | Koers | Variatie | Volume |
---|---|---|---|
30-04-24 | 1,57 | -1,88% | 246 620 |
29-04-24 | 1,6 | +1,91% | 784 906 |
26-04-24 | 1,57 | -1,57% | 239 955 |
25-04-24 | 1,595 | -0,31% | 306 541 |
24-04-24 | 1,6 | -1,23% | 288 059 |
uitgestelde koers Nasdaq, 30 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
+11,35% | 107 mln. | |
+0,17% | 42,19 mld. | |
+10,92% | 42,24 mld. | |
+44,30% | 40,15 mld. | |
-6,20% | 28,31 mld. | |
+5,23% | 24,63 mld. | |
-24,79% | 18,2 mld. | |
+26,69% | 12,01 mld. | |
-3,13% | 11,76 mld. | |
+6,57% | 10,4 mld. |